Ginkgetin attenuates bone loss in OVX mice by inhibiting the NF-κB/IκBα signaling pathway

GeJin Wei1, Xiongbo Liang2, Feng Wu1

  • 1Department of Orthopaedics, 923rd Hospital of PLA, Nanning, China.

Peerj
|July 15, 2024
PubMed
Abstract

Insights

Ginkgetin, a natural compound, was found to protect against bone loss in ovariectomized mice. It inhibits osteoclast formation by suppressing the NF-κB/IκBα pathway, offering a potential treatment for osteoporosis.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Osteoporosis Research

Background:

  • Osteoporosis is characterized by excessive osteoclast activation and bone resorption.
  • Ginkgetin, derived from ginkgo leaves, possesses anti-inflammatory and antioxidant properties.
  • This study explores ginkgetin's bone-protective effects in an osteoporosis model.

Purpose of the Study:

  • To investigate the bone-protective effects of ginkgetin in ovariectomized (OVX) mice.
  • To elucidate the underlying signaling pathway involved in ginkgetin's inhibition of osteoclastogenesis.
  • To evaluate ginkgetin's therapeutic potential for osteoporosis.

Main Methods:

  • Biochemical assays (Ca, ALP, P), micro CT scanning, and histopathological analysis (H&E, TRAP staining) were used.
  • Gene expression of osteoclast markers (ctsk, c-fos, trap) was analyzed via RT-PCR.
  • Western blot was employed to assess the NF-κB/IκBα signaling pathway.

Main Results:

  • Ginkgetin treatment influenced serum mineral levels and inhibited bone loss in OVX mice.
  • TRAP staining and RT-PCR confirmed ginkgetin's suppression of osteoclast generation and related gene expression.
  • Ginkgetin inhibited the phosphorylation of NF-κB p65 and IκBα proteins.

Conclusions:

  • Ginkgetin attenuates bone loss in OVX mice by inhibiting osteoclast formation and activation.
  • The mechanism involves the suppression of the NF-κB/IκBα signaling pathway.
  • Ginkgetin demonstrates potential as a therapeutic agent for osteoporosis.